Botulinum toxin therapy in urology: historical aspect

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅存取

详细

The review article shows the main stages of studying botulinum toxin and its use in medicine. The possibilities of using botulinum toxin for the treatment of urological patients are similarly described. Furthermore, the most significant studies on the use of botulinum toxin in patients with neurogenic detrusor c, idiopathic overactive bladder, detrusor sphincter dyssynergia, chronic pelvic pain, benign prostatic hyperplasia, erectile dysfunction, and premature ejaculation are presented.

作者简介

Grigorii Krivoborodov

Pirogov Russian National Research Medical University

Email: dr.krivoborodov@yandex.ru
ORCID iD: 0000-0001-6433-4219
SPIN 代码: 8431-1205
Scopus 作者 ID: 6602856939

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow

Igor Kuzmin

Academician I.P. Pavlov First St. Petersburg State Medical University

编辑信件的主要联系方式.
Email: kuzminigor@mail.ru
ORCID iD: 0000-0002-7724-7832
SPIN 代码: 2684-4070
Scopus 作者 ID: 56878681300

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Saint Petersburg

Margarita Slesarevskaya

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: mns-1971@yandex.ru
ORCID iD: 0000-0002-4911-6018
SPIN 代码: 9602-7775
Scopus 作者 ID: 57196117211

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Saint Petersburg

Nikolay Efremov

Pirogov Russian National Research Medical University

Email: nefr@yandex.ru
ORCID iD: 0000-0001-7785-3405
SPIN 代码: 1453-4148

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Moscow

Alina Gontar

Pirogov Russian National Research Medical University

Email: drgontar@yandex.ru
ORCID iD: 0000-0002-7072-4026
俄罗斯联邦, Moscow

参考

  1. Grüsser OJ. The first systematic descriptions and animal experiment studies of botulism. On the 200th birthday of Justinus Kerner 18 September 1986. Sudhoffs Arch. 1986;70(2):167–287. (In German)
  2. Kerner J. Vergiftung durch verdorbene Würste. Tübinger Blätter für Naturwissenschaften und Arzneykunde. 1817;3:1–25. (In German)
  3. Erbguth FJ, Naumann M. Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”. Neurology. 1999;53(8):1850–1853. doi: 10.1212/wnl.53.8.1850
  4. Devriese PP. On the discovery of Clostridium botulinum. J Hist Neurosci. 1999;8(1):43–50. doi: 10.1076/jhin.8.1.43.1774
  5. Van Ermengem EP. Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus. Zeitschrift für Hygiene und Infektionskrankheiten. 1897;26(1):1–56. (In German) doi: 10.1007/BF02220526
  6. Leuchs J. Beiträge zur Kenntnis des Toxins und Antitoxins des Bacillus botulinus. Zeitschrift für Hygiene und Infektionskrankheiten. 1910;65: 55–84. (In German) doi: 10.1007/BF0228411410
  7. Burke GS. The occurrence of bacillus botulinus in nature. J Bacteriol. 1919;4(5):541–553. doi: 10.1128/jb.4.5.541-553.1919
  8. Edmunds CW, Keiper GF. Further studies on the action of botulinum toxin. JAMA. 1924;83(7):495–502. doi: 10.1001/jama.1924.02660070011006
  9. Burgen AS, Dickens F, Zatman LJ. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949;109(1–2):10–24. doi: 10.1113/jphysiol.1949.sp0043
  10. Drachman DB. Atrophy of skeletal muscles in chicks embryo treated with botulinum toxin. Science. 1964;145(3633):719–721. doi: 10.1126/science.145.3633.719
  11. Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12(12):924–927.
  12. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10): 1044–1049. doi: 10.1016/s0161-6420(80)35127-0
  13. Dykstra DD, Sidi AA, Scott AB, et al. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J Urol. 1988;139(5):919–922. doi: 10.1016/s0022-5347(17)42717-0
  14. Schurch B, Stöhrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000;164(3–1):692–697. doi: 10.1097/00005392-200009010-00018
  15. Mazo EВ, Krivoborodov GG, Shkolnikov ME. Botulinictoxin in patients with neurogenic dysfunction of the lower urinary tracts. Urologiia. 2004;(4):44–48. EDN: OKLEKZ
  16. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200. doi: 10.1097/01.ju.0000162035.73977.1
  17. Cruz F, Herschorn S, Aliotta P, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–750. doi: 10.1016/j.eururo.2011.07.002
  18. Ginsberg D, Gousse A, Keppenne V, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6): 2131–2139. doi: 10.1016/j.juro.2012.01.125
  19. Kennelly M, Cruz F, Herschorn S, et al. Efficacy and safety of abobotulinumtoxinA in patients with neurogenic detrusor overactivity incontinence performing regular clean intermittent catheterization: Pooled results from two phase 3 randomized studies (CONTENT1 and CONTENT2). Eur Urol. 2022;82(2):223–232. doi: 10.1016/j.eururo.2022.03.010
  20. Krivoborodov GG, Kuzmin IV, Romikh VV. Abobotulinum toxin A (Dysport®) for the treatment of neurogenic detrusor overactivity. Urologiia. 2023;(2):122–129. EDN: CBOGMK doi: 10.18565/urology.2023.2.122-12
  21. Radziszewski P, Dobronski A, Borkowski A. Treatment of the non — neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A — a pilot study [abstract]. Neurourol Urodyn. 2001;20:410–412.
  22. Sahai A, Khan MS, Dasgupta P, GKT Botulinum Study Group. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–2236. doi: 10.1016/j.juro.2007.01.130
  23. Dmochowski R, Chapple C, Nitti VW, et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol. 2010;184(6):2416–2422. doi: 10.1016/j.juro.2010.08.021
  24. Krivoborodov GG, Vasiliev AV, Shumilo DV, et al. Botulinum toxin type A in patients with overactive bladder. Urologiia. 2010;(3):36–40. EDN: MTZCFB
  25. Fowler CJ, Auerbach S, Ginsberg D, et al. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol. 2012;62(1):148–157. doi: 10.1016/j.eururo.2012.03.005
  26. Denys P, Le Normand L, Ghout I, et al. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61(3): 520–529. doi: 10.1016/j.eururo.2011.10.028
  27. Chapple C, Sievert K-D, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–256. doi: 10.1016/j.eururo.2013.04.001
  28. Nitti VW, Dmochowski R, Herschorn S, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–2193. doi: 10.1016/j.juro.2012.12.022
  29. Kuzmin IV, Slesarevskaya MN, Amdiy RE, et al. Long-term botulinum therapy for overactive bladder: myths and reality. Urology reports (St. Petersburg). 2022;12(1):71–84. EDN: OYTVRD doi: 10.17816/uroved104335
  30. Gallien P, Reymann JM, Amarenco G, et al. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76(12):1670–1676. doi: 10.1136/jnnp.2004.045765
  31. Mazo ЕВ, Krivoborodov GG, Efremov NS. Botulinum A toxin in the treatment of patients with detrusor external sphincter dyssynergia and neurogenic low detrusor contractility. Therapeutic archive. 2008;80(10):49–52. EDN: JFEURN
  32. Tsai S-J, Ying T-H, Huang Y-H, et al. Transperineal injection of botulinum toxin A for treatment of detrusor sphincter dyssynergia: localization with combined fluoroscopic and electromyographic guidance. Arch Phys Med Rehabil. 2009;90(5):832–836. doi: 10.1016/j.apmr.2008.10.023
  33. Kuo H-C. Satisfaction with urethral injection of botulinum toxin A for detrusor sphincter dyssynergia in patients with spinal cord lesion. Neurourol Urodyn. 2008;27(8):793–796. doi: 10.1002/nau.20606
  34. Chen S-L, Bih L-I, Chen G-D, et al. Transrectal ultrasound-guided transperineal botulinum toxin A injection to the external urethral sphincter for treatment of detrusor external sphincter dyssynergia in patients with spinal cord injury. Arch Phys Med Rehabil. 2010;91(3):340–344. doi: 10.1016/j.apmr.2009.11.006
  35. Maria G, Brisinda G, Civello IM, et al. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology. 2003;62(2):259–264. doi: 10.1016/s0090-4295(03)00477-1
  36. Crawford ED, Hirst K, Kusek JW, et al. Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial. J Urol. 2011;186(3):965–970. doi: 10.1016/j.juro.2011.04.062
  37. Marberger M, Chartier-Kastler E, Egerdie B, et al. A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol. 2013;63(3):496–503. doi: 10.1016/j.eururo.2012.10.005
  38. McVary KT, Roehrborn CG, Chartier-Kastler E, et al. A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2014;192(1):150–156. doi: 10.1016/j.juro.2014.02.004
  39. Shim SR, Cho YJ, Shin I-S, Kim JH. Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48(1):19–30. doi: 10.1007/s11255-015-1153-3
  40. Tavakkoli M, Ghorbani H, Nobahar A, et al. Transurethral intraprostatic botulinum toxin-A injection in patients with benign prostatic hyperplasia: A case series and literature review. Iran J Toxicol. 2022;16(1):9–16. doi: 10.32598/IJT.16.1.851.1
  41. Moussa AS, Ragheb AM, Abdelbary AM, et al. Outcome of Botulinum Toxin-A intraprostatic injection for benign prostatic hyperplasia induced lower urinary tract symptoms: A prospective multicenter study. Prostate. 2019;79(11):1221–1225. doi: 10.1002/pros.23805
  42. Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–875. doi: 10.1016/j.urology.2004.06.073
  43. Giannantoni A, Costantini E, Di Stasi SM, et al. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur Urol. 2006;49(4):704–709. doi: 10.1016/j.eururo.2005.12.002
  44. Pinto R, Lopes T, Costa D, et al. Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A. Urology. 2014;83(5):1030–1034. doi: 10.1016/j.urology.2014.01.018
  45. Pinto R, Lopes T, Frias B, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol. 2010;58(3):360–365. doi: 10.1016/j.eururo.2010.02.031
  46. Kuo H-C, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104(5):657–661. doi: 10.1111/j.1464-410X.2009.08495.x
  47. Kuo H-C, Jiang Y-H, Tsai Y-C, Kuo Y-C. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment — A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol Urodyn. 2016;35(5):609–614. doi: 10.1002/nau.22760
  48. Al-Shukri SH, Kuzmin IV, Slesarevskaya MN, Ignashov YuA. Botulinum toxin type A in the treatment of bladder pain syndrome in women: initial results. Urology reports (St. Petersburg). 2018; 8(2):5–10. EDN: XTMHAL doi: 10.17816/uroved825-10
  49. Hanno PM, Erickson D, Moldwin R, et al. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–1553. doi: 10.1016/j.juro.2015.01.086
  50. Engeler D, Baranowski AP, Berghmans B, et al. EAU guidelines on chronic pelvic pain. European Association of Urology, 2024.
  51. Zermann D-H, Ishigooka M, Schubert J, Schmidt RA. Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur Urol. 2000;38(4):393–399. doi: 10.1159/000020314
  52. Gottsch HP, Yang CC, Berger RE. A pilot study of botulinum toxin A for male chronic pelvic pain syndrome. Scand J Urol Nephrol. 2011;45(1):72–76. doi: 10.3109/00365599.2010.529820
  53. Krivoborodov GG, Shumilo DV, Vasiliev AV, et al. Botulinic toxin type A in combined treatment of males with chronic pelvic pain syndrome in combination with bladder emptying dysfunction. Urologiia. 2011;(5):67–72. EDN: OKLGYJ
  54. Falahatkar S, Shahab E, Gholamjani Moghaddam K, Kazemnezhad E. Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double-blind and randomized placebo-controlled study. BJU Int. 2015;116(4):641–649. doi: 10.1111/bju.12951
  55. El-Enen MA, Abou-Farha M, El-Abd A, et al. Intraprostatic injection of botulinum toxin-A in patients with refractory chronic pelvic pain syndrome: The transurethral vs. transrectal approach. Arab J Urol. 2015;13(2):94–99. doi: 10.1016/j.aju.2015.01.001
  56. Jarvis SK, Abbott JA, Lenart MB, et al. Pilot study of botulinum toxin type A in the treatment of chronic pelvic pain associated with spasm of the levator ani muscles. Aust N Z J Obstet Gynaecol. 2004;44(1):46–50. doi: 10.1111/j.1479-828X.2004.00163.x
  57. Abbott JA, Jarvis SK, Lyons SD, et al. Botulinum toxin type A for chronic pain and pelvic floor spasm in women: a randomized controlled trial. Obstet Gynecol. 2006;108(4):915–923. doi: 10.1097/01.AOG.0000237100.29870.cc
  58. Ghanem H, Raheem AA, AbdelRahman IFS, et al. Botulinum neurotoxin and its potential role in the treatment of erectile dysfunction. Sex Med Rev. 2018;6(1):135–142. doi: 10.1016/j.sxmr.2017.07.008
  59. El-Shaer W, Ghanem H, Diab T, et al. Intra-cavernous injection of BOTOX® (50 and 100 Units) for treatment of vasculogenic erectile dysfunction: Randomized controlled trial. Andrology. 2021;9(4): 1166–1175. doi: 10.1111/andr.13010
  60. Abdelrahman IFS, Raheem AA, Elkhiat Y, et al. Safety and efficacy of botulinum neurotoxin in the treatment of erectile dysfunction refractory to phosphodiesterase inhibitors: Results of a randomized controlled trial. Andrology. 2022;10(2):254–261. doi: 10.1111/andr.13104
  61. Giuliano F, Joussain C, Denys P. Safety and efficacy of intracavernosal injections of abobotulinumtoxinA (Dysport®) as add on therapy to phosphosdiesterase type 5 inhibitors or prostaglandin e1 for erectile dysfunction-case studies. Toxins (Basel). 2019;11(5):283. doi: 10.3390/toxins11050283
  62. Giuliano F, Joussain C, Denys P, et al. Intracavernosal onabotulinumtoxina exerts a synergistic pro-erectile effect when combined with sildenafil in spontaneously hypertensive rats. J Sex Med. 2022;19(6):899–906. doi: 10.1016/j.jsxm.2022.03.213
  63. Serefoglu EC, Silay MS. Botulinum toxin-A injection may be beneficial in the treatment of life-long premature ejaculation. Med Hypotheses. 2010;74(1):83–84. doi: 10.1016/j.mehy.2009.07.038
  64. Shaher H, Noah K, Abdelzaher M, et al. Is bulbospongiosus muscle botox injection safe and effective in treating lifelong premature ejaculation? Randomized controlled study. World J Urol. 2024;42(1):218. doi: 10.1007/s00345-024-04899-1
  65. Almekaty K, Ghaith A, Ragab M, et al. Effect of bulbospongiosus muscle injection with botulinum-A toxin for treatment of lifelong premature ejaculation; a randomized controlled trial. Int J Impot Res. 2024; In print. doi: 10.1038/s41443-024-00831-8

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Emile van Ermengem (1851–1932)

下载 (84KB)
索引源数据
3. Fig. 2. Alan Scott (1932–2021)

下载 (84KB)
索引源数据

版权所有 © Eco-Vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
 


##common.cookie##